Valencic E, Grasso AGiacomo, Conversano E, Lucafò M, Piscianz E, Gregori M, Conti F, Cancrini C, Tommasini A. Theophylline as a precision therapy in a young girl with PIK3R1 immunodeficiency. J Allergy Clin Immunol Pract 2018;6(6):2165-2167.

Marcuzzi A, Piscianz E, Valencic E, Monasta L, Brumatti LVecchi, Tommasini A. To Extinguish the Fire from Outside the Cell or to Shutdown the Gas Valve Inside? Novel Trends in Anti-Inflammatory Therapies. Int J Mol Sci 2015;16(9):21277-93.

Bianco AMonica, Faletra F, Vozzi D, Girardelli M, Knowles A, Tommasini A, Zauli G, Marcuzzi A. Two?gene mutation in a single patient: Biochemical and functional analysis for a correct interpretation of exome results. Mol Med Rep 2015;12(4):6128-32.

Franca R, Rebora P, Athanasakis E, Favretto D, Verzegnassi F, Basso G, Tommasini A, Valsecchi MGrazia, Decorti G, Rabusin M. TNF-? SNP rs1800629 and risk of relapse in childhood acute lymphoblastic leukemia: relation to immunophenotype. Pharmacogenomics 2014;15(5):619-27.

De Leo L, Marcuzzi A, Decorti G, Tommasini A, Crovella S, Pontillo A. Targeting farnesyl-transferase as a novel therapeutic strategy for mevalonate kinase deficiency: in vitro and in vivo approaches. Pharmacol Res 2010;61(6):506-10.

Freudenberg F, Wintergerst U, Roesen-Wolff A, Albert MH, Prell C, Strahm B, Koletzko S, Ehl S, Roos D, Tommasini A, Ventura A, Belohradsky BH, Seger R, Roesler J, Güngör T. Therapeutic strategy in p47-phox deficient chronic granulomatous disease presenting as inflammatory bowel disease. J Allergy Clin Immunol 2010;125(4):943-946.e1.